Antiplasmin, but not amiloride, prevents synovitis and cartilage damage following hemarthrosis in hemophilic mice

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 2, 2014, Pages 237-245

  Nieuwenhuizen, L ^a,b   Roosendaal, G ^b   Mastbergen, S C ^a   Coeleveld, K ^a   Biesma, D H ^b,c   Lafeber, F P J G ^a   Schutgens, R E G ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Amiloride; Antiplasmins; Arthropathy; Erosive; Hemarthrosis; Hemophilia

Indexed keywords

AMILORIDE; ANTIPLASMIN; HEMATOXYLIN; PLACEBO; PLASMIN; PROTEOGLYCAN;

ANIMAL EXPERIMENT; ARTICLE; CARTILAGE INJURY; CONTROLLED STUDY; HEMARTHROSIS; HEMOPHILIA; HISTOLOGY; KNEE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SAFRANIN O SCORE; SCORING SYSTEM; SYNOVIAL FLUID LEVEL; SYNOVITIS; VALENTINO SCORE;

AMILORIDE; ANTIPLASMINS; ARTHROPATHY; EROSIVE; HEMARTHROSIS; HEMOPHILIA;

AMILORIDE; ANIMALS; ANTIFIBRINOLYTIC AGENTS; CARTILAGE; HEMARTHROSIS; HEMOPHILIA A; MICE; SYNOVITIS;

EID: 84893575913     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12467     Document Type: Article

References (28)

1. Lafeber FP, Miossec P, Valentino LA. Physiopathology of haemophilic arthropathy. Haemophilia 2008; 14(Suppl. 4): 3-9.
2. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12(Suppl. 3): 117-21.
3. Jansen NW, Roosendaal G, Lafeber FP. Understanding haemophilic arthropathy: an exploration of current open issues. Br J Haematol 2008; 143: 632-40.
4. Nieuwenhuizen L, Roosendaal G, Coeleveld K, Lubberts E, Biesma DH, Lafeber FP, Schutgens RE. Haemarthrosis stimulates the synovial fibrinolytic system in haemophilic mice. Thromb Haemost 2013; 110: 173-83.
5. So AK, Varisco PA, Kemkes-Matthes B, Herkenne-Morard C, Chobaz-Peclat V, Gerster JC, Busso N. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 2003; 1: 2510-15.
6. Hakobyan N, Enockson C, Cole AA, Sumner DR, Valentino LA. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia 2008; 14: 804-9.
7. Ali A, Ahmad FJ, Pillai KK, Vohora D. Amiloride protects against pentylenetetrazole-induced kindling in mice. Br J Pharmacol 2005; 145: 880-4.
8. Klinghofer V, Stewart K, McGonigal T, Smith R, Sarthy A, Nienaber V, Butler C, Dorwin S, Richardson P, Weitzberg M, Wendt M, Rockway T, Zhao X, Hulkower KI, Giranda VL. Species specificity of amidine-based urokinase inhibitors. Biochemistry 2001; 40: 9125-31.
9. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, Schwarzenberger P, van de Loo FA, van den Berg WB. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001; 167: 1004-13.
10. Valentino LA, Hakobyan N. Histological changes in murine haemophilic synovitis: a quantitative grading system to assess blood-induced synovitis. Haemophilia 2006; 12: 654-62.
11. Rosenberg L. Chemical basis for the histological use of safranin O in the study of articular cartilage. J Bone Joint Surg Am 1971; 53: 69-82.
12. Crippa MP. Urokinase-type plasminogen activator. Int J Biochem Cell Biol 2007; 39: 690-4.
13. Del Rossi M, Fibbi G, Matucci CM. The urokinase-type plasminogen activator system and inflammatory joint diseases. Clin Exp Rheumatol 1999; 17: 485-98.
14. Fibbi G, Pucci M, Serni U, Cerinic MM, Del Rosso M. Antisense targeting of the urokinase receptor blocks urokinase-dependent proliferation, chemoinvasion, and chemotaxis of human synovial cells and chondrocytes in vitro. Proc Assoc Am Physicians 1998; 110: 340-50.
15. Ronday HK, Smits HH, Quax PH, van der Pluijm G, Lowik CW, Breedveld FC, Verheijen JH. Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. Br J Rheumatol 1997; 36: 9-15.
16. Avery RL, Connor TB Jr, Farazdaghi M. Systemic amiloride inhibits experimentally induced neovascularization. Arch Ophthalmol 1990; 108: 1474-6.
17. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays 1993; 15: 105-11.
18. Busso N, Peclat V, van Ness K, Kolodziesczyk E, Degen J, Bugge T, So A. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest 1998; 102: 41-50.
19. Kikuchi H, Tanaka S, Matsuo O. Plasminogen activator in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1987; 14: 439-45.
20. Jin T, Tarkowski A, Carmeliet P, Bokarewa M. Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis. Arthritis Res Ther 2003; 5: R9-17.
21. Yang YH, Carmeliet P, Hamilton JA. Tissue-type plasminogen activator deficiency exacerbates arthritis. J Immunol 2001; 167: 1047-52.
22. Furmaniak-Kazmierczak E, Cooke TD, Manuel R, Scudamore A, Hoogendorn H, Giles AR, Nesheim M. Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage. J Clin Invest 1994; 94: 472-80.
23. Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol 2005; 166: 783-92.
24. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17: 439-44.
25. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13066-76.
26. Monea S, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol 2002; 192: 160-70.
27. Hvas AM, Sorensen HT, Norengaard L, Christiansen K, Ingerslev J, Sorensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007; 5: 2408-14.
28. Rainsford SG, Jouhar AJ, Hall A. Tranexamic acid in the control of spontaneous bleeding in severe haemophilia. Thromb Diath Haemorrh 1973; 30: 272-9.